Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moleculin Biotech, Inc. shareholders approved Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal at the 2023-10-03 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-10-03
Exact text from the filing
Proposal 2. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal (the “Adjournment Proposal”), by the following vote: Votes For Votes Against Abstain 10,036,330 6,686,830 101,528
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moleculin Biotech, Inc. shareholders approved To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common at the 2023-10-03 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-10-03
Exact text from the filing
Proposal 1. To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-5 and 1-for-20 as determined by the Board in its sole discretion, prior to the one-year anniversary of this Special Meeting (the “Reverse Split Proposal”), by the following vote: Votes For Votes Against Abstain 9,796,443 6,858,043 170,202
View on SEC.gov